Findings hoped to spur the development of an improved vaccine
Since 2000, U.S. infants have been routinely immunized against pneumococcal (Streptococcus pneumoniae) infection. Now, Boston researchers have made a surprising discovery about natural immunity to pneumococcus. Two related studies, led by Dr. Richard Malley of the Childrens Hospital Boston Division of Infectious Diseases and Dr. Marc Lipsitch of the Harvard School of Public Health, suggest that natural protection from pneumococcal disease may derive from some previously unrecognized immune mechanism, which could possibly be exploited for a new vaccine. The latest study appears in the current (March 29) issue of the Proceedings of the National Academy of Sciences.
In the U.S., before the advent of the pneumococcal conjugate vaccine, known as Prevnar, S. pneumoniae caused more than 7 million ear infections each year, half a million episodes of bacterial pneumonia, and life-threatening cases of meningitis and bacteremia. Prevnar is made up of material from the outer capsule of each of the seven pneumococcal strains most common in the U.S. This material triggers recipients immune systems to produce so-called anticapsular antibodies specific to those strains. However, Prevnar doesnt work against many pneumococcal strains in the developing world, where pneumococcus kills nearly 1 million children annually, and it is expensive and difficult to manufacture, leading to chronic shortages. Moreover, in several studies, use of pneumococcal conjugate vaccines caused non-vaccine strains to become more common, raising concerns that Prevnar could eventually become ineffective even in the U.S. Of 90 known pneumococcal strains, Prevnar only covers seven.
Susan Craig | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News